Cargando…
1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253541/ http://dx.doi.org/10.1093/ofid/ofy210.1076 |
_version_ | 1783373519214608384 |
---|---|
author | Smith, Bradley Rivera, Christina Dierkhising, Ross Estes, Lynn O’Horo, John Tande, Aaron Zeuli, John Virk, Abinash |
author_facet | Smith, Bradley Rivera, Christina Dierkhising, Ross Estes, Lynn O’Horo, John Tande, Aaron Zeuli, John Virk, Abinash |
author_sort | Smith, Bradley |
collection | PubMed |
description | BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017. The primary objective of the study compared rates of therapy modification due to drug-related toxicity for staphylococcal infections treated with ceftriaxone, cefazolin, nafcillin, oxacillin, vancomycin, daptomycin, ceftaroline, linezolid, or ertapenem. Secondary objectives included determination of the frequency and type of adverse drug events (ADEs) attributed to OPAT and rate of readmission due to ADEs attributed to OPAT. RESULTS: One hundred seventy-two patients were identified (cefazolin n = 54, ceftriaxone n = 49, vancomycin n = 30, daptomycin n = 16, nafcillin n = 9, ertapenem n = 6, ceftaroline n = 4, oxacillin n = 3, linezolid n = 1). The overall treatment completion rates were high (153/172, 89.0%). Patients completed an average of 35.3 days (7 to 95) of therapy with their original antibiotic. Fourteen patients required change to a different antibiotic due to antimicrobial toxicity (ceftriaxone=5; vancomycin=2; cefazolin = 2; daptomycin = 2; ceftaroline = 1; nafcillin = 1; oxacillin = 1) and five patients experienced treatment failure required an additional agent (ceftriaxone = 2; nafcillin = 2; linezolid = 1). Adverse drug events (ADEs) were the most common reason for antimicrobial adjustment (14/19, 73.7%). The most common ADEs were hypokalemia (28/172, 16.3%) and diarrhea (25/172, 14.5%). There were only two cases of Clostridium difficile. Thirty-day readmissions due to antimicrobial therapy were low with 11 patients. CONCLUSION: OPAT with Gram-positive agents used for staphylococcal infections is effective, but antimicrobial modifications still occur. Clinicians should be aware of the risk of ADEs and readmissions in OPAT patients. A multidisciplinary approach may enhance management of ADEs and possibly preventing readmissions DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62535412018-11-28 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections Smith, Bradley Rivera, Christina Dierkhising, Ross Estes, Lynn O’Horo, John Tande, Aaron Zeuli, John Virk, Abinash Open Forum Infect Dis Abstracts BACKGROUND: Limited data exist to evaluate safety-related outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) patients treated with antimicrobial agents for Gram-positive infections. METHODS: This retrospective, single-center study enrolled Mayo Clinic OPAT patients between 2013 and 2017. The primary objective of the study compared rates of therapy modification due to drug-related toxicity for staphylococcal infections treated with ceftriaxone, cefazolin, nafcillin, oxacillin, vancomycin, daptomycin, ceftaroline, linezolid, or ertapenem. Secondary objectives included determination of the frequency and type of adverse drug events (ADEs) attributed to OPAT and rate of readmission due to ADEs attributed to OPAT. RESULTS: One hundred seventy-two patients were identified (cefazolin n = 54, ceftriaxone n = 49, vancomycin n = 30, daptomycin n = 16, nafcillin n = 9, ertapenem n = 6, ceftaroline n = 4, oxacillin n = 3, linezolid n = 1). The overall treatment completion rates were high (153/172, 89.0%). Patients completed an average of 35.3 days (7 to 95) of therapy with their original antibiotic. Fourteen patients required change to a different antibiotic due to antimicrobial toxicity (ceftriaxone=5; vancomycin=2; cefazolin = 2; daptomycin = 2; ceftaroline = 1; nafcillin = 1; oxacillin = 1) and five patients experienced treatment failure required an additional agent (ceftriaxone = 2; nafcillin = 2; linezolid = 1). Adverse drug events (ADEs) were the most common reason for antimicrobial adjustment (14/19, 73.7%). The most common ADEs were hypokalemia (28/172, 16.3%) and diarrhea (25/172, 14.5%). There were only two cases of Clostridium difficile. Thirty-day readmissions due to antimicrobial therapy were low with 11 patients. CONCLUSION: OPAT with Gram-positive agents used for staphylococcal infections is effective, but antimicrobial modifications still occur. Clinicians should be aware of the risk of ADEs and readmissions in OPAT patients. A multidisciplinary approach may enhance management of ADEs and possibly preventing readmissions DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253541/ http://dx.doi.org/10.1093/ofid/ofy210.1076 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Smith, Bradley Rivera, Christina Dierkhising, Ross Estes, Lynn O’Horo, John Tande, Aaron Zeuli, John Virk, Abinash 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title | 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title_full | 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title_fullStr | 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title_full_unstemmed | 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title_short | 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections |
title_sort | 1243. comparative analysis of antimicrobial-related adverse events in the outpatient treatment of staphylococcal infections |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253541/ http://dx.doi.org/10.1093/ofid/ofy210.1076 |
work_keys_str_mv | AT smithbradley 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT riverachristina 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT dierkhisingross 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT esteslynn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT ohorojohn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT tandeaaron 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT zeulijohn 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections AT virkabinash 1243comparativeanalysisofantimicrobialrelatedadverseeventsintheoutpatienttreatmentofstaphylococcalinfections |